Unnamed: 0,title,date,stock,sentiment
1306516.0,VBL Presents New Data On Potential Of Novel Anti-MOSPD2 Monoclonal Antibodies For Rheumatoid Arthritis At EULAR 2020 Congress,2020-06-04 07:16:00-04:00,VBLT,positive
1306517.0,Vascular Biogenics F-1 Filing Shows Registration For ~11.49M Share Stock Offering Via Selling Shareholders,2020-06-01 12:25:00-04:00,VBLT,positive
1306518.0,"VBL Presents Interim Data From OVAL Phase 3 Pivotal Study In Ovarian Cancer At ASCO20 Annual Meeting, Showing 58% Or Higher Objective Response Rate",2020-06-01 07:14:00-04:00,VBLT,negative
1306519.0,"VBL Presents Interim Data From OVAL Phase 3 Pivotal Study In Ovarian Cancer At ASCO20 Annual Meeting, Showing 58% Or Higher Objective Response Rate",2020-06-01 07:14:00-04:00,VBLT,negative
1306520.0,Recap: Vascular Biogenics Q1 Earnings,2020-05-14 08:38:00-04:00,VBLT,neutral
1306521.0,"The Daily Biotech Pulse: ASCO Abstracts Create Stock Ripples, Applied DNA's Coronavirus Test Receives EUA, Biopharmx Shareholders Vet Reverse Merger",2020-05-14 08:32:00-04:00,VBLT,positive
1306522.0,"Vascular Biogenics Q1 EPS $(0.150) Beats $(0.170) Estimate, Sales $366.000K Beat $160.000K Estimate",2020-05-14 07:03:00-04:00,VBLT,neutral
1306523.0,"The Week Ahead In Biotech: Virtual Conference Presentations, Clovis PDUFA Date In The Spotlight",2020-05-10 15:40:00-04:00,VBLT,neutral
1306524.0,"The Daily Biotech Pulse: FDA Approves Novartis Lung Cancer Drug, 2-Way Contest Emerging For Tetraphase Pharma, Dexcom To Join S&P 500",2020-05-07 07:41:00-04:00,VBLT,negative
1306525.0,VBL Presents New Data On MOSPD2 Antibodies As Potential Treatment For NASH And Colitis At DDW,2020-05-06 07:19:00-04:00,VBLT,neutral
1306526.0,17 Healthcare Stocks Moving In Wednesday's Pre-Market Session,2020-04-22 07:38:00-04:00,VBLT,neutral
1306527.0,"The Daily Biotech Pulse: Applied DNA Begins Validating COVID-19 Test, Cara's Positive Readout, Novan Explores Strategic Alternatives",2020-04-21 08:19:00-04:00,VBLT,positive
1306528.0,VBL Therapeutics Awarded 3.2M NIS Non-Dilutive Grant By The Israel Innovation Authority For VB-111,2020-04-21 07:05:00-04:00,VBLT,positive
1306529.0,"Oppenheimer Maintains Outperform on Vascular Biogenics, Raises Price Target to $3",2020-04-17 09:06:00-04:00,VBLT,neutral
1306530.0,VBL Therapeutics Says its VB-201 Has Reached a Milestone and the Company Will Receive a Cash Payment at an Undisclosed Amount,2020-04-06 07:05:00-04:00,VBLT,positive
1306531.0,VBL Therapeutics Reports Its Japanese Licensee NanoCarrior To Extend Ongoing Phase 3 OVAL Trial In Ovarian Cancer,2020-04-02 09:08:00-04:00,VBLT,negative
1306532.0,"VBL Therapeutics Announces Its OVAL Phase 3 Ovarian Cancer Pivotal Study Met The Interim Pre-specified Criterion, Of An Absolute Percentage Advantage Of 10% Or Higher In Ca-125 Response In The Vb-111 Treated Arm Compared To Control",2020-03-26 07:57:00-04:00,VBLT,negative
1306533.0,Vascular Biogenics: Q4 Earnings Insights,2020-03-19 10:33:00-04:00,VBLT,neutral
1306534.0,"The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection",2020-03-19 07:37:00-04:00,VBLT,neutral
1306535.0,"Earnings Scheduled For March 19, 2020",2020-03-19 04:54:00-04:00,VBLT,neutral
1306536.0,"The Week Ahead In Biotech: COVID-19 Updates, Tapering Earnings Flow, Eton's Seizure Drug Review",2020-03-15 09:55:00-04:00,VBLT,neutral
1306537.0,"VBL Therapeutics Announces The Launch Of A New Clinical Trial Of VB-111 Combined With The Checkpoint Inhibitor, Nivolumab, In Metastatic Colorectal Cancer",2020-02-20 08:13:00-05:00,VBLT,negative
1306538.0,50 Healthcare Stocks Moving In Wednesday's Pre-Market Session,2020-01-08 08:31:00-05:00,VBLT,neutral
1306539.0,VBL Therapeutics Highlights Publication Of Phase 2 And Phase 3 Data Of VB-111 In Recurrent Glioblastoma Supporting Continued Development In Investigator-Sponsored Study,2020-01-08 08:19:00-05:00,VBLT,positive
1306540.0,Vascular Biogenics Granted European Patent Titled Formulations And Dosage Forms Of Oxidized Phospholipids,2019-12-11 11:46:00-05:00,VBLT,positive
1306541.0,"The Daily Biotech Pulse: Amarin Braces For Vascepa Adcom Verdict, Biotechs On A Fundraising Spree, Zosano Makes Progress With Migraine Drug Filing",2019-11-14 08:07:00-05:00,VBLT,positive
1306542.0,"VBL Therapeutics Q3 EPS $(0.14), Inline, Sales $79K Miss $120K Estimate",2019-11-14 07:13:00-05:00,VBLT,negative
1306543.0,"The Week Ahead In Biotech: Adcom Test For Amarin's Fish Oil Pill, Agile Awaits FDA Verdict",2019-11-10 16:08:00-05:00,VBLT,positive
1306544.0,VBL Therapeutics Announces New IND For An Investigator-Sponsored Phase 2 Trial Of VB-111 In Recurrent Glioblastoma,2019-11-06 08:13:00-05:00,VBLT,neutral
1306545.0,"The Daily Biotech Pulse: Jazz Goes Shopping, Portola Offering, Novelion Delays Quarterly Results",2019-08-13 07:25:00-04:00,VBLT,neutral
1306546.0,"Vascular Biogenics Q2 EPS $(0.13), Inline, Sales $138K Beat $120K Estimate",2019-08-13 07:24:00-04:00,VBLT,neutral
1306547.0,"The Week Ahead In Biotech: Vanda Awaits FDA Decision, BioVie Plans IPO",2019-08-11 15:46:00-04:00,VBLT,positive
1306548.0,"Oppenheimer Initiates Coverage On Vascular Biogenics with Outperform Rating, Announces $2 Price Target",2019-06-27 08:04:00-04:00,VBLT,neutral
1306549.0,"VBL Therapeutics Reports Radiographic Analysis of VB-111 Phase 2, 3 Clinical Trials in Recurrent Glioblastoma Shows Survival Benefit Associated with Objective Responses and Distinct Signature of VB-111 Activity",2019-06-03 08:08:00-04:00,VBLT,positive
1306550.0,VBL Therapeutics Reports Final Phase 1/2 Results Presented At ASCO Showed VB-111 Dose Dependent Increase in Overall Survival and 58% CA-125 Response Rate in Platinum-Resistant Ovarian Cancer,2019-06-03 08:07:00-04:00,VBLT,negative
1306551.0,"The Daily Biotech Pulse: FDA Greenlights Pfizer-Merck KGAa's Kidney Cancer Combo Treatment, Adcom Disappointment For Daiichi",2019-05-15 07:50:00-04:00,VBLT,negative
1306552.0,"Vascular Biogenics Q1 EPS $(0.12), Inline, Sales $219K Miss $1.15M Estimate",2019-05-15 07:15:00-04:00,VBLT,negative
1306553.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings And IPOs",2019-05-11 08:40:00-04:00,VBLT,neutral
1306554.0,CEO Of VBLT Saying They Are In Talks With Big Pharma About A Possible Deal 'We'Ve Been 'Dancing' With Huge Companies -  Soon We'Ll Be Able To Tell About A Deal',2019-04-17 13:48:00-04:00,VBLT,positive
1306555.0,"The Daily Biotech Pulse: Blueprint Medicine Expedites Clinical Programs, Eyepoint Offering, Precision Biosciences IPO",2019-03-28 07:54:00-04:00,VBLT,neutral
1306556.0,"Earnings Scheduled For March 28, 2019",2019-03-28 04:09:00-04:00,VBLT,neutral
1306557.0,36 Stocks Moving In Tuesday's Pre-Market Session,2019-03-19 08:10:00-04:00,VBLT,neutral
1306558.0,VBL Highlights Presentation Of New Data On Potential Of VB-111 To Stimulate The Immune System And Drive Immune Cells To Infiltrate Tumor Microenvironment,2019-03-19 07:11:00-04:00,VBLT,positive
1306559.0,VBL Therapeutics Awarded $2.9M Non-Dilutive Grant By The Israel Innovation Authority,2019-02-20 08:12:00-05:00,VBLT,positive
1306560.0,"VBL Therapeutics Will Present Data On Novel VB-600 Platform At Keystone Conference Feb. 26, 2019",2019-02-19 08:23:00-05:00,VBLT,positive
1306561.0,"The Daily Biotech Pulse: Proteostasis Delays Data, Akron Gets New CEO, Pfizer Halts Vaccine Trial",2018-12-21 07:58:00-05:00,VBLT,neutral
1306562.0,"The Daily Biotech Pulse: Pfizer-Glaxo Set Up Consumer Health Care Venture, New Patent For Adamas",2018-12-19 07:46:00-05:00,VBLT,positive
1306563.0,"Stocks Which Set New 52-Week Low Yesterday, Wed., Nov. 28, 2018",2018-11-29 10:59:00-05:00,VBLT,negative
1306564.0,"Vascular Biogenics Q3 EPS $(0.15) Up From $(0.24) YoY, Sales $100K Miss $300K Estimate",2018-11-20 07:01:00-05:00,VBLT,negative
1306565.0,"Stocks Which Set New 52-Week Lows Fri., Nov. 16, 2018",2018-11-19 10:16:00-05:00,VBLT,negative
1306566.0,"The Daily Biotech Pulse: Mallinckrodt FDA Verdict, European Cheer For Bristol-Myers Squibb, Morphosys Clinches Licensing Deal",2018-11-16 08:08:00-05:00,VBLT,positive
1306567.0,"UPDATE: VBL Therapeutics Says Patients In GLOBE Study 'had relatively high tumor volume, as large-volume tumors were not an exclusion criterion'",2018-11-16 07:10:00-05:00,VBLT,negative
1306568.0,VBL Therapeutics Reports Results From Phase 3 GLOBE Study In Patients With Recurrent Gliablastoma,2018-11-16 07:09:00-05:00,VBLT,neutral
1306569.0,"Stocks Which Set New 52-Week Low Yesterday, Wed., Nov. 14, 2018",2018-11-15 11:37:00-05:00,VBLT,negative
1306570.0,"The Daily Biotech Pulse: FDA Nod For Mallinckrodt's Pain Drug, AbbVie-Neurocrine Report Positive Elagolix Results",2018-11-15 08:10:00-05:00,VBLT,positive
1306571.0,"The Daily Biotech Pulse: Mallinckrodt Faces FDA Panel, Reshape's Earnings, Vapotherm To Debut",2018-11-14 08:17:00-05:00,VBLT,neutral
1306572.0,"The Daily Biotech Pulse: Pfizer And Allergan Earnings, CFO Departures At Acadia And Assertio",2018-10-30 08:00:00-04:00,VBLT,neutral
1306573.0,VBL Therapeutics Granted a European Commission Patent for VB-111 Until October 2033,2018-10-23 08:06:00-04:00,VBLT,positive
1306574.0,"The Daily Biotech Pulse: Eiger's Lymphoedema Drug Study Fails, Roche's Sales Rise",2018-10-17 08:15:00-04:00,VBLT,negative
1306575.0,"The Daily Biotech Pulse: Enzo's Q4 Loss, Sanofi's Positive Trial Results, ImmunoCellular To Delist",2018-10-16 08:52:00-04:00,VBLT,positive
1306576.0,"Benzinga's Top Upgrades, Downgrades For October 15, 2018",2018-10-15 09:27:00-04:00,VBLT,positive
1306577.0,"H.C. Wainwright Upgrades Vascular Biogenics to Buy, Maintains $3 Price Target",2018-10-15 07:14:00-04:00,VBLT,neutral
1306578.0,"The Daily Biotech Pulse: FDA Thumbs Down For Trevena, Corium To Go Private, Immune Design Discontinues Cancer Vaccine Program",2018-10-12 07:34:00-04:00,VBLT,negative
1306579.0,VBL Therapeutics Highlights Publication Of New Data On Lecinoxoid Drug Candidates For Treatment Of Renal Fibrosis In 'Basic and Clinical Pharmacology and Toxicology',2018-08-30 07:20:00-04:00,VBLT,neutral
1306580.0,"Stocks Which Set New 52-Week Low Yesterday, August 16th",2018-08-17 10:40:00-04:00,VBLT,negative
1306581.0,"The Daily Biotech Pulse: No Anxiety For Biohaven, Strongbridge's About-Face, Bristol-Myers Squibb's FDA Wait",2018-08-16 09:37:00-04:00,VBLT,negative
1306582.0,28 Stocks Moving In Thursday's Pre-Market Session,2018-08-16 08:03:00-04:00,VBLT,neutral
1306583.0,"Vascular Biogenics Q2 EPS $(0.13) Beats $(0.18) Estimate, Sales $200K Miss $300K Estimate",2018-08-16 07:01:00-04:00,VBLT,negative
1306584.0,"Earnings Scheduled For August 16, 2018",2018-08-16 04:17:00-04:00,VBLT,neutral
1306585.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings And IPOs",2018-08-12 16:52:00-04:00,VBLT,neutral
1306586.0,"Stocks Which Set New 52-Week Low Yesterday, August 8th",2018-08-09 11:10:00-04:00,VBLT,negative
1306587.0,"Stocks Which Set New 52-Week Low Yesterday, August 7th",2018-08-08 11:06:00-04:00,VBLT,negative
1306588.0,"The Daily Biotech Pulse: FDA Panel Backs Insmed, Eidos' Maiden Earnings, Paratek Awaits Adcom Verdict",2018-08-08 08:15:00-04:00,VBLT,positive
1306589.0,"Stocks Which Set New 52-Week Low Yesterday, August 6th",2018-08-07 11:28:00-04:00,VBLT,negative
1306590.0,"The Daily Biotech Pulse: FDA Snub For Gemphire, Ligand Earnings, Insmed's Antibiotic Faces FDA Panel",2018-08-07 08:23:00-04:00,VBLT,negative
1306591.0,"Stocks Which Set New 52-Week Low Yesterday, August 2nd",2018-08-03 11:22:00-04:00,VBLT,negative
1306592.0,"The Daily Biotech Pulse: Zafgen Executive Departs; Adamas, Acceleron Accelerate On Earnings",2018-08-03 07:52:00-04:00,VBLT,neutral
1306593.0,"Stocks Which Set New 52-Week Low Yesterday, July 30th",2018-07-31 09:25:00-04:00,VBLT,negative
1306594.0,Stocks Which Set New 52-Week Low Yesterday,2018-07-20 07:56:00-04:00,VBLT,negative
1306595.0,Publication By VBL Therapeutics Highlights MOSPD2 As A Potential New Target For Breast Cancer Therapy,2018-07-10 08:07:00-04:00,VBLT,negative
1306596.0,CVI Investments Reports 5.3% Stake In Vascular Biogenics,2018-07-03 09:53:00-04:00,VBLT,neutral
1306597.0,54 Biggest Movers From Yesterday,2018-06-27 04:51:00-04:00,VBLT,neutral
1306598.0,40 Stocks Moving In Tuesday's Mid-Day Session,2018-06-26 12:32:00-04:00,VBLT,neutral
1306599.0,Sabby Reports New 5.31% Stake In Vascular Biogenics,2018-06-26 10:46:00-04:00,VBLT,neutral
1306600.0,VBL Therapeutics Reports $15.5M Registered Direct Offering Priced At The Market,2018-06-26 09:00:00-04:00,VBLT,neutral
1306601.0,45 Biggest Movers From Yesterday,2018-06-08 04:07:00-04:00,VBLT,neutral
1306602.0,36 Stocks Moving In Thursday's Mid-Day Session,2018-06-07 12:30:00-04:00,VBLT,neutral
1306603.0,40 Biggest Movers From Yesterday,2018-06-07 04:50:00-04:00,VBLT,neutral
1306604.0,Mid-Afternoon Market Update: Dow Rises Over 200 Points; Ambarella Shares Slide On Weak Sales Forecast,2018-06-06 14:31:00-04:00,VBLT,negative
1306605.0,"Benzinga Pro's Top 10 Most-Searched Tickers For Afternoon Of Wed., Jun. 6, 2018",2018-06-06 12:48:00-04:00,VBLT,positive
1306606.0,28 Stocks Moving In Wednesday's Mid-Day Session,2018-06-06 12:24:00-04:00,VBLT,neutral
1306607.0,Mid-Day Market Update: Crude Oil Down 1.5%; Axovant Shares Spike Higher,2018-06-06 12:09:00-04:00,VBLT,negative
1306608.0,Mid-Morning Market Update: Markets Mostly Higher; Signet Jewelers Earnings Top Estimates,2018-06-06 10:16:00-04:00,VBLT,positive
1306609.0,"Benzinga's Daily Biotech Pulse: Vascular Biogenics Soars On Positive Platform Data, Axovant Licenses Parkinson's Candidate",2018-06-06 08:38:00-04:00,VBLT,positive
1306610.0,24 Stocks Moving In Wednesday's Pre-Market Session,2018-06-06 08:12:00-04:00,VBLT,neutral
1306611.0,5 Stocks Moving In Tuesday's After-Hours Session,2018-06-05 17:54:00-04:00,VBLT,neutral
1306612.0,"VBL Therapeutics Shares Up 34.9% After Co. Announced It Will Present t Data On Novel MOSPD2 Program In Oncology, Inflammation At BIO Convention",2018-06-05 16:28:00-04:00,VBLT,positive
1306613.0,"VBL Therapeutics Reports Will Present Data On Novel MOSPD2 Program In Oncology, Inflammation At BIO Convention; Highlights Data Indicating MOSPD2 Is Required For Directional Movement Of Tumor cells, Certain Immune Cells",2018-06-05 16:03:00-04:00,VBLT,positive
1306614.0,24 Stocks Moving In Friday's Pre-Market Session,2018-05-18 08:04:00-04:00,VBLT,neutral
1306615.0,7 Stocks Moving In Thursday's After-Hours Session,2018-05-17 16:52:00-04:00,VBLT,neutral
1306616.0,"Benzinga's Daily Biotech Pulse: ASCO Abstracts, Fibrocell, Ispen And More",2018-05-17 08:27:00-04:00,VBLT,neutral
1306617.0,"Vascular Biogenics Q1 EPS $(0.24) Misses $(0.20) Estimate, Sales $163K Beat $150K Estimate",2018-05-17 07:12:00-04:00,VBLT,negative
1306618.0,"Earnings Scheduled For May 17, 2018",2018-05-17 04:06:00-04:00,VBLT,neutral
1306619.0,B Riley Likes Tocagen On Prospects For Company's Brain Cancer Drug,2018-05-16 12:27:00-04:00,VBLT,negative
1306620.0,"The Week Ahead In Biotech: PDUFA Dates, Earnings, IPOs And More",2018-05-13 10:06:00-04:00,VBLT,neutral
1306621.0,VBL Therapeutics Wins a $2.5M Grant From the Israel Innovation Authority,2018-04-09 08:10:00-04:00,VBLT,positive
1306622.0,"VBL Therapeutics Reports FY17 EPS $(0.37) vs $(0.57) Est., Sales $13.864M vs $10M Est.",2018-03-15 07:16:00-04:00,VBLT,neutral
1306623.0,"Benzinga's Top Upgrades, Downgrades For March 9, 2018",2018-03-09 09:29:00-05:00,VBLT,positive
1306624.0,Chardan Capital Downgrades Vascular Biogenics to Neutral,2018-03-09 06:56:00-05:00,VBLT,neutral
1306625.0,56 Biggest Movers From Yesterday,2018-03-09 04:51:00-05:00,VBLT,neutral
1306626.0,"Vascular Biogenics Shares Down 63% After Phase 3 GLOBE Study Didn't Meet Primary Endpoint, H.C. Wainwright Downgraded Stock to Neutral",2018-03-08 14:32:00-05:00,VBLT,positive
1306627.0,Mid-Afternoon Market Update: Dow Turns Lower; Express Scripts Shares Climb On Acquisition News,2018-03-08 14:31:00-05:00,VBLT,neutral
1306628.0,45 Stocks Moving In Thursday's Mid-Day Session,2018-03-08 12:31:00-05:00,VBLT,neutral
1306629.0,Mid-Day Market Update: Comtech Telecomm Rises Following Strong Q2 Results; Vascular Biogenics Shares Fall,2018-03-08 12:10:00-05:00,VBLT,positive
1306630.0,H.C. Wainwright Downgrades Vascular Biogenics to Neutral,2018-03-08 11:46:00-05:00,VBLT,neutral
1306631.0,Mid-Morning Market Update: Markets Open Higher; American Eagle Posts In-Line Profit,2018-03-08 10:19:00-05:00,VBLT,positive
1306632.0,32 Stocks Moving In Thursday's Pre-Market Session,2018-03-08 08:06:00-05:00,VBLT,neutral
1306633.0,VBL Therapeutics Phase 3 GLOBE Study Did Not Meet Its Pre-Specified Primary Endpoint Of Overall Survival,2018-03-08 06:06:00-05:00,VBLT,neutral
1306634.0,"VBL Therapeutics Receives a Milestone Payment From NanoCarrier, Terms Not Disclosed",2018-02-08 07:38:00-05:00,VBLT,neutral
1306635.0,VBL Therapeutics Announces the First Patient in its Phase 3 Study of VB-111,2017-12-27 07:03:00-05:00,VBLT,neutral
1306636.0,"VBL Therapeutics Reports First Patient in Pivotal Phase 3 Study of VB-111 in Platinum Resistant Ovarian Cancer in Partnership with the GOG Foundation, Inc.",2017-12-27 07:00:00-05:00,VBLT,negative
1306637.0,Vascular Biogenics F-3 Filing Shows Registration For $150M Mixed Securities Shelf Offering,2017-12-18 17:10:00-05:00,VBLT,positive
1306638.0,VBL Therapeutics Says New Biomarker Data Supports Direct Link between VB-111's Dual Mechanism of Action and its Clinical Effect on Overall Survival and Progression Free Survival in Recurrent Glioblastoma Multiforme Patients,2017-12-18 08:28:00-05:00,VBLT,positive
1306639.0,45 Biggest Movers From Friday,2017-11-20 05:09:00-05:00,VBLT,neutral
1306640.0,Mid-Afternoon Market Update: Crude Oil Up Over 2%; Foot Locker Shares Rise On Earnings Beat,2017-11-17 14:31:00-05:00,VBLT,negative
1306641.0,35 Stocks Moving In Friday's Mid-Day Session,2017-11-17 12:27:00-05:00,VBLT,neutral
1306642.0,Mid-Day Market Update: Abercrombie & Fitch Climbs After Q3 Beat; Century Casinos Shares Drop,2017-11-17 12:00:00-05:00,VBLT,neutral
1306643.0,Mid-Morning Market Update: Markets Open Lower; Foot Locker Tops Q3 Expectations,2017-11-17 10:08:00-05:00,VBLT,positive
1306644.0,VBL Therapeutics Reports Pricing Of 2.5M Share Common Stock Offering For $18.75M,2017-11-17 09:02:00-05:00,VBLT,positive
1306645.0,31 Stocks Moving In Friday's Pre-Market Session,2017-11-17 08:13:00-05:00,VBLT,neutral
1306646.0,VBL Therapeutics Reports Proposed Public Offering of 2.5M Shares of Ordinary Shares,2017-11-16 16:02:00-05:00,VBLT,positive
1306647.0,VBL Therapeutics Reports Q3 EPS $(0.24) vs $(0.20) Est.,2017-11-14 07:10:00-05:00,VBLT,neutral
1306648.0,31 Stocks Moving In Monday's Mid-Day Session,2017-11-06 12:45:00-05:00,VBLT,neutral
1306649.0,"VBL Therapeutics and NanoCarrier Co., Ltd. Sign Exclusive Agreement for VB-111 in Japan, VBL To Receive $15M Upgront And Is Entitled To Receive $100M In Development And Commercial Milestone Payments",2017-11-06 07:04:00-05:00,VBLT,positive
1306650.0,"UPDATE:  VBL Therapeutics to Receive up-front Payment of $15M, $100M+ in Development and Commercial Milestone Payments",2017-11-06 04:55:00-05:00,VBLT,neutral
1306651.0,Nanocarrier Signs Exclusive Agreement with VBL Therapeutics for VB-111 in Japan,2017-11-06 04:45:00-05:00,VBLT,positive
1306652.0,VBL Therapeutics Reports Orphan Drug Designation for VB-111 in Europe,2017-10-20 07:01:00-04:00,VBLT,neutral
1306653.0,UPDATE: VBL Says Topline Data Expected In Q1'18,2017-10-02 07:26:00-04:00,VBLT,neutral
1306654.0,UPDATE: VBL Says DSMC Unanimously Recommended Study Continue As Planned To Completion,2017-10-02 07:25:00-04:00,VBLT,positive
1306655.0,UPDATE: VBL Says DSMC Confirmed No Added Follow Up Will Be Necessary,2017-10-02 07:25:00-04:00,VBLT,negative
1306656.0,"VBL Therapeutics Reports Outcome In Third, Final DSMC Review Of Phase 3 GLOBE Trial Of VB-111 In Recurrent GBM: Safety Concerns Were Not Identified",2017-10-02 07:25:00-04:00,VBLT,positive
1306657.0,"VBL Therapeutics Reports Positive DSMC Recommendation That Supports Safety Of VB-111, Expects Top-Line Data In Q1 2018",2017-10-02 07:04:00-04:00,VBLT,positive
1306658.0,22 Stocks Moving In Tuesday's Pre-Market Session,2017-09-26 08:10:00-04:00,VBLT,neutral
1306659.0,15 Biggest Mid-Day Losers For Wednesday,2017-09-20 12:46:00-04:00,VBLT,negative
1306660.0,"VBL Therapeutics Q2 EPS $(0.18) vs $(0.19) Est., No Sales",2017-08-14 07:13:00-04:00,VBLT,negative
1306661.0,"Earnings Scheduled For August 14, 2017",2017-08-14 04:42:00-04:00,VBLT,neutral
1306662.0,VBL Therapeutics Offers Long-Term Survival In Phase 2 Trials Of Patients With Multiple Tumor Types,2017-06-19 08:05:00-04:00,VBLT,negative
1306663.0,VBL Therapeutics Names Corinne Epperly COO,2017-06-15 07:03:00-04:00,VBLT,neutral
1306664.0,VBL Therapeutics Wins $2.5M Grant,2017-06-08 07:13:00-04:00,VBLT,positive
1306665.0,Vascular Biogenics Gives Update on Phase 2 Trial,2017-06-05 07:44:00-04:00,VBLT,neutral
1306666.0,"VBL Therapeutics Q1 EPS $(0.19) vs $(0.16) Est, No Sales",2017-05-15 07:26:00-04:00,VBLT,negative
1306667.0,VBL Therapeutics Shows Data on VB-111 in Combination with Checkpoint Inhibitor at the 20th Annual ASGCT Meeting,2017-05-11 07:07:00-04:00,VBLT,negative
1306668.0,VBL Therapeutics +.70 After-Hours @$5.90 After Co Reports Positive DSMC Review In Phase 3 GLOBE Trial Of VB-111,2017-04-20 16:23:00-04:00,VBLT,positive
1306669.0,VBL Therapeutics Reports Positive DSMC Review In Phase 3 GLOBE Trial Of VB-111,2017-04-20 16:04:00-04:00,VBLT,positive
1306670.0,"H.C. Wainwright Holding NASH Investor Conference Today; Attendees Include Allergan, Enanta Pharma, Madrigal Pharma, Vascular Biogenics, Albireo Pharma, CymaBay, Gemphire Therapeutics, And Galectin Therapeutics",2017-04-03 08:28:00-04:00,VBLT,neutral
1306671.0,"H.C. Wainwright Reiterates Buy On Vascular Biogenics Ltd., Maintains $11 Price Target",2017-03-28 07:14:00-04:00,VBLT,neutral
1306672.0,"VBL Therapeutics FY 2016 EPS $(0.64) vs $(0.66) Est, No Sales",2017-03-27 07:32:00-04:00,VBLT,negative
1306673.0,"Earnings Scheduled For March 27, 2017",2017-03-27 05:38:00-04:00,VBLT,neutral
1306674.0,15 Biggest Mid-Day Gainers For Thursday,2017-03-23 12:29:00-04:00,VBLT,neutral
1306675.0,VBL Tehrapeutics Phase 2 Study Of VB-111 Met Primary Endpoint Of 6-Month Progression Free Survival,2017-02-21 07:15:00-05:00,VBLT,positive
1306676.0,VBL Therapeutics Completes Enrollment in the Pivotal GLOBE Study,2017-01-06 07:02:00-05:00,VBLT,neutral
1306677.0,VBL Therapeutics Reports Positive DSMC Review in Phase 3 GLOBE Trial Investigating VB-111 in rGBM,2016-12-05 07:00:00-05:00,VBLT,positive
1306678.0,15 Biggest Mid-Day Gainers For Tuesday,2016-11-29 12:32:00-05:00,VBLT,neutral
1306679.0,"Roth Capital Out Positive On Vascular Biogenics, Expects Large Pharma Partnership Based On Ovarian Cancer Program, Reiterates $17 PT and Buy Rating",2016-11-29 10:34:00-05:00,VBLT,negative
1306680.0,CombiMatrix's Pre-Implantation Genetic Screening Approval Highlights Today's Pre-Market Biotech Roundup,2016-11-29 09:42:00-05:00,VBLT,positive
1306681.0,20 Stocks Moving In Tuesday's Pre-Market Session,2016-11-29 08:22:00-05:00,VBLT,neutral
1306682.0,"VBL Therapeutics Says VB-111 Met Primary Endpoint, Shows Evidence Of Overall Survival Benefit",2016-11-29 07:07:00-05:00,VBLT,positive
1306683.0,VBL Therapeutics Reports Q3 EPS $(0.12) vs. Est. $(0.15),2016-11-10 07:25:00-05:00,VBLT,neutral
1306684.0,VBL Therapeutics Announces Plans to Establish New Manufacturing Facility  For Potential Commercialization Of VB-111,2016-10-13 09:05:00-04:00,VBLT,neutral
1306685.0,15 Stocks That Rallied For Three Days On No News,2016-10-13 07:05:00-04:00,VBLT,negative
1306686.0,Vascular Biogenics Pops to High of $4.31  on Volume,2016-09-07 10:04:00-04:00,VBLT,neutral
1306687.0,Vascular Biogenics Shares Off Highs at $4.25; Traders Indicating to Stake of Lee Family May Not be New; Filing Contains Information Regarding Collection of Debt from Keffi VI,2016-08-25 12:05:00-04:00,VBLT,negative
1306688.0,Thai Lee Reports 21.6% Stake in VBLT in 13D,2016-08-25 11:55:00-04:00,VBLT,neutral
1306689.0,"VBL Therapeutics Q2 EPS ($0.14) vs ($0.23) est, No Revenue",2016-08-15 07:08:00-04:00,VBLT,negative
1306690.0,VBL Therapeutics Reports Q2 EPS $(0.14) vs. Est. $(0.23),2016-08-15 07:02:00-04:00,VBLT,neutral
1306691.0,H.C. Wainwright Sees Nearly 200% Upside In Vascular Biogenics,2016-06-28 10:11:00-04:00,VBLT,neutral
1306692.0,The Market In 5 Minutes: Stocks Start To Recover From Brexit Onslaught,2016-06-28 09:05:00-04:00,VBLT,neutral
1306693.0,15 Stocks Moving In Friday's Pre-Market Session,2016-06-17 08:18:00-04:00,VBLT,neutral
1306694.0,Vascular Biogenics Spikes to High of $4.60 on Vol,2016-06-16 15:30:00-04:00,VBLT,neutral
1306695.0,Vascular Biogenics Spikes to High of $4.28 on Vol,2016-06-16 12:56:00-04:00,VBLT,neutral
1306696.0,Vascular Biogenics Spikes to High of $5.22 on Vol,2016-06-10 10:46:00-04:00,VBLT,neutral
1306697.0,8 Biggest Mid-Day Losers For Tuesday,2016-06-07 12:50:00-04:00,VBLT,negative
1306698.0,"Vascular Biogenics Jumped 80%, But 'Provocative' OvCa Data Will Provide Further Clinical Validation",2016-06-07 10:45:00-04:00,VBLT,neutral
1306699.0,Mid-Morning Market Update: Markets Mostly Higher; Valeant Earnings Miss Views,2016-06-07 10:03:00-04:00,VBLT,negative
1306700.0,12 Stocks Moving In Tuesday's Pre-Market Session,2016-06-07 08:27:00-04:00,VBLT,neutral
1306701.0,Vascular Biogenics Reports $24M Registered Direct Offering,2016-06-07 07:45:00-04:00,VBLT,neutral
1306702.0,Mid-Afternoon Market Update: Helios and Matheson Analytics Jumps Amid News Of Merger With Zone Technologies; ProNAi Therapeutics Shares Drop,2016-06-06 14:31:00-04:00,VBLT,neutral
1306703.0,"Roth Capital Reiterates Buy Rating, $22 Target on Vascular Biogenics Amid 83% Gain in Stock Today",2016-06-06 14:17:00-04:00,VBLT,positive
1306704.0,9 Biggest Mid-Day Gainers For Monday,2016-06-06 12:17:00-04:00,VBLT,neutral
1306705.0,Vascular Biogenics Surges 80% Off Double Catalyst,2016-06-06 12:06:00-04:00,VBLT,neutral
1306706.0,Mid-Day Market Update: Dow Surges Over 100 Points; Adamis Pharmaceuticals Shares Slide,2016-06-06 12:05:00-04:00,VBLT,positive
1306707.0,Mid-Morning Market Update: Markets Open Higher; Devon Energy To Sell Non-Core Upstream Assets For Around $1 Billion,2016-06-06 10:09:00-04:00,VBLT,positive
1306708.0,Unconfirmed Chatter That Vascular Biogenics May Be Takeover Candidate For Bristol Myers Squibb,2016-06-06 10:03:00-04:00,VBLT,negative
1306709.0,10 Stocks Moving In Monday's Pre-Market Session,2016-06-06 08:30:00-04:00,VBLT,neutral
1306710.0,Pre Market Movers,2016-06-06 08:00:00-04:00,VBLT,neutral
1306711.0,"VBL Therapeutics VB-111 Showed Significant Increase In Overall Survival At Therapeutic vs. Low Dose Level, 60% Durable Repsonse Rate; Trial Designed To Evaluate Safety, Tolerability, and Explore Efficacy",2016-06-06 07:04:00-04:00,VBLT,positive
1306712.0,VBL Therapeutics Spikes to $6.66 Following  VB-111 News,2016-06-03 16:09:00-04:00,VBLT,neutral
1306713.0,VBL Therapeutics Reports Data Presented at ASCO Showed Significant Overall Survival Benefit in rGBM Patients Receiving VB-111 vs Historical Avastin,2016-06-03 16:07:00-04:00,VBLT,positive
1306714.0,"VBL Therapeutics Reports Q1 EPS $(0.21), Inline",2016-05-13 08:02:00-04:00,VBLT,neutral
1306715.0,"Earnings Scheduled For May 13, 2016",2016-05-13 04:06:00-04:00,VBLT,neutral
1306716.0,VBL Therapeutics Announces Clinical Data to be Presented at 2016 ASCO Annual Meeting,2016-05-03 11:08:00-04:00,VBLT,neutral
1306717.0,Vascular Biogenics Spikes to High of $3.68 on Vol,2016-05-03 11:07:00-04:00,VBLT,neutral
1306718.0,"VBL Therapeutics Reports Publication of NASH Data for Lecinoxoids Molecules VB-201, VB-703",2016-04-19 08:05:00-04:00,VBLT,neutral
1306719.0,VBL Therapeutics Reports FY15 EPS $(0.73) vs. Prior Year $(3.09),2016-03-29 08:02:00-04:00,VBLT,neutral
1306720.0,"Earnings Scheduled For March 29, 2016",2016-03-29 04:15:00-04:00,VBLT,neutral
1306721.0,VBL Therapeutics Reports Launch of First Israeli Site Related to GLOBE Int'l Pivotal Trial for VB-111,2016-02-22 08:15:00-05:00,VBLT,neutral
1306722.0,Newly Granted US Composition of Matter Patent Extends Exclusive Protection for VBL Therapeutics' Lead Drug Candidate VB-111 Until October 2033,2015-12-01 08:04:00-05:00,VBLT,positive
1306723.0,VBL Therapeutics Reports Significant Improvement of 12 Month Overall Survival With VB-111 Compared to Pooled Data From Four Avastin Studies at the Annual Meeting of the Society for Neuro-Oncology,2015-11-19 08:01:00-05:00,VBLT,positive
1306724.0,VBL Therapeutics Reports Q3 EPS $(0.29) vs. Est. $(0.19),2015-11-12 07:04:00-05:00,VBLT,neutral
1306725.0,Benzinga's Top Initiations,2015-11-09 09:50:00-05:00,VBLT,positive
1306726.0,Piper Jaffray Initiates Coverage on Vascular Biogenics at Overweight,2015-11-09 08:26:00-05:00,VBLT,negative
1306727.0,Piper Jaffray Initiates Coverage on Vascular Biogenics at Overweight,2015-11-09 06:45:00-05:00,VBLT,negative
1306728.0,Vascular Biogenics Reports Pricing Of 2.5M Shares At $6/Share,2015-11-03 09:24:00-05:00,VBLT,positive
1306729.0,"VBL Therapeutics Presents Positive Data on VB-111 in Advanced Radioactive Iodine Refractory Differentiated Thyroid Cancer at the ITC 2015 Conference, Met Primary Endpoint",2015-10-21 16:02:00-04:00,VBLT,positive
1306730.0,Morning Market Gainers,2015-09-28 09:46:00-04:00,VBLT,neutral
1306731.0,Benzinga's Top #PreMarket Losers,2015-09-28 08:25:00-04:00,VBLT,negative
1306732.0,"VBL Therapeutics Announces Phase 2 Data from Trial of VB-111 in rGBM, Says Met Primary Endpoint of Statistically-Significant Increase in Overall Survival",2015-09-28 08:13:00-04:00,VBLT,positive
1306733.0,Benzinga's Volume Movers,2015-09-24 10:33:00-04:00,VBLT,neutral
1306734.0,Morning Market Losers,2015-09-23 09:57:00-04:00,VBLT,negative
1306735.0,"A $6 Stock Hitting $25? Vascular Biogenics Could, Chardan Says",2015-09-22 12:37:00-04:00,VBLT,neutral
1306736.0,Benzinga's Volume Movers,2015-09-22 10:40:00-04:00,VBLT,neutral
1306737.0,Morning Market Gainers,2015-09-22 09:57:00-04:00,VBLT,neutral
1306738.0,"Monday's After-Hours Movers Led By Vascular Biogenics, Ultragenyx And Red Hat",2015-09-22 09:11:00-04:00,VBLT,neutral
1306739.0,Benzinga's Top #PreMarket Gainers,2015-09-22 08:19:00-04:00,VBLT,positive
1306740.0,"Chardan Capital Initiates Coverage on Vascular Biogenics at Buy, Announces $25.00 PT",2015-09-21 16:08:00-04:00,VBLT,neutral
1306741.0,Morning Market Gainers,2015-09-18 09:44:00-04:00,VBLT,neutral
1306742.0,VBL Therapeutics to Present Complete Phase 2 Data on VB-111 in Combination With Bevacizumab in Recurrent GBM at the European Cancer Conference,2015-09-17 16:01:00-04:00,VBLT,negative
1306743.0,VBL Therapeutics Reports Initial Patient Dosed in Important Phase 3 Trial of VB-111 in Recurrent Glioblastoma,2015-08-20 08:01:00-04:00,VBLT,positive
1306744.0,6-K from Vascular Biogenics Shows Q2 Loss of $0.15/Share vs Loss of $0.17/Share Est.,2015-08-13 06:15:00-04:00,VBLT,negative
1306745.0,16 Biotech Stocks Moving Off The ASCO Conference,2015-06-01 15:51:00-04:00,VBLT,neutral
1306746.0,Benzinga's Top #PreMarket Gainers,2015-06-01 08:08:00-04:00,VBLT,positive
1306747.0,Adam Feuerstein @adamfeuerstein Tweet: $VBLT is not presenting its suspect GBM data at ASCO. Misleading press release.,2015-06-01 07:35:00-04:00,VBLT,negative
1306748.0,VBL Therapeutics Announces Updated Interim Results From Phase 2 Clinical Trial of VB-111 in Recurrent Glioblastoma,2015-06-01 07:31:00-04:00,VBLT,neutral
1306749.0,VBL Therapeutics Shares Rise 25% Premarket Following Presentation of Phase 1/2a Data from VB-111 in Recurrent Platinum-Resistant Mullerian Cancer at ASCO,2015-06-01 07:07:00-04:00,VBLT,negative
1306750.0,VBL Therapeutics to Present Phase 1/2a Data from VB-111 in Recurrent Platinum-Resistant Mullerian Cancer at ASCO,2015-05-30 20:26:00-04:00,VBLT,negative
1306751.0,"Roth Capital Initiates Coverage on Vascular Biogenics at Buy, Announces $13.00 PT",2015-05-22 05:48:00-04:00,VBLT,neutral
1306752.0,Morning Market Gainers,2015-05-14 09:44:00-04:00,VBLT,neutral
1306753.0,VBL Therapeutics Reports Will Present Phase 1/2 Data for VB-111 in Recurrent Platinum-Resistant Mullerian Cancer at ASCO,2015-05-13 17:03:00-04:00,VBLT,negative
1306754.0,Oppenheimer Assumes Vascular Biogenics at Perform,2015-04-27 08:29:00-04:00,VBLT,neutral
1306755.0,Morning Market Gainers,2015-03-25 09:37:00-04:00,VBLT,neutral
1306756.0,Benzinga's Top #PreMarket Gainers,2015-03-25 08:15:00-04:00,VBLT,positive
1306757.0,US Stock Futures Flat Ahead Of Durable-Goods Orders Data,2015-03-25 07:26:00-04:00,VBLT,neutral
1306758.0,VBL Therapeutics Q4 EPS -$0.23 vs -$0.24 est,2015-03-25 07:03:00-04:00,VBLT,neutral
1306759.0,VBL Therapeutics Reports Interim Topline Results From Phase 2 Clinical Trial of VB-111 in Recurrent Glioblastoma,2015-03-25 07:01:00-04:00,VBLT,neutral
1306760.0,"SeaWorld, Mattress Firm Lead Thursday's After-Hours Movers",2015-03-19 17:49:00-04:00,VBLT,neutral
1306761.0,JMP Securities Downgrades Vascular Biogenics to Market Perform,2015-02-17 13:03:00-05:00,VBLT,positive
1306762.0,Morning Market Losers,2015-02-17 09:53:00-05:00,VBLT,negative
1306763.0,Benzinga's Top #PreMarket Losers,2015-02-17 08:20:00-05:00,VBLT,negative
1306764.0,"VBL Therapeutics to Discontinue Development of VB-201 in Ulcerative Colitis, Psoriasis Following Phase 2 Results",2015-02-17 07:35:00-05:00,VBLT,neutral
1306765.0,VBL Therapeutics Announces Removal of FDA Partial Clinical Hold on VB-111,2015-02-17 07:31:00-05:00,VBLT,neutral
1306766.0,VBL Therapeutics Receives European Patent Issuance on Lecinoxoid Platform Technology,2015-02-06 08:07:00-05:00,VBLT,neutral
1306767.0,Deutsche Bank Raises Vascular Biogenics Price Target,2015-01-22 09:38:00-05:00,VBLT,neutral
1306768.0,VBL Therapeutics Announces Positive Phase 2a Data for VB-111 in Recurrent Thyroid Cancer,2014-12-22 08:32:00-05:00,VBLT,negative
1306769.0,VBL Therapeutics Announces Last Patient Out in Phase 2 Clinical Studies of VB-201 in Psoriasis and Ulcerative Colitis,2014-12-15 08:38:00-05:00,VBLT,neutral
1306770.0,VBL Therapeutics to Present Interim Phase 2 Data From VB-111 In Recurrent Glioblastoma At 19th Annual Scientific Meeting Of The Society For Neuro-Oncology,2014-11-13 07:07:00-05:00,VBLT,neutral
1306771.0,VBL Therapeutics to Present Interim Phase 2 Data From VB-111 in Recurrent Glioblastoma ,2014-11-03 08:45:00-05:00,VBLT,neutral
1306772.0,Stocks Hitting 52-Week Highs,2014-10-08 10:02:00-04:00,VBLT,neutral
1306773.0,"Shares of Vascular Biogenics Open for Trade at $6.02, IPO Priced at $6/Share",2014-10-01 10:00:00-04:00,VBLT,positive
1306774.0,Expected IPOs For October 1,2014-10-01 09:16:00-04:00,VBLT,neutral
1306775.0,Updated Filing from Vascular Biogenics Shows Co. Expecting to Sell ~6.666M Shares at $6/Share in IPO,2014-09-30 10:35:00-04:00,VBLT,positive
